Abstract
Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy. (1) At 8 weeks, morning and evening peak expiratory flow rates were significantly improved in the salmeterol group only (p < 0.01). (2) Symptom and sleeplessness scores improved in the order, salmeterol (symptom score; p < 0.0001), inhaled corticosteroid add-on, and tulobuterol groups. (3) Only the salmeterol group showed significant improvement in the total Asthma Quality of Life Questionnaire score (p < 0.05). (4) No adverse reactions considered related to the study drugs were observed.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Administration, Cutaneous
-
Adrenal Cortex Hormones / administration & dosage*
-
Adrenal Cortex Hormones / adverse effects
-
Adult
-
Aged
-
Albuterol / administration & dosage
-
Albuterol / adverse effects
-
Albuterol / analogs & derivatives*
-
Anti-Inflammatory Agents / administration & dosage*
-
Anti-Inflammatory Agents / adverse effects
-
Asthma / diagnosis
-
Asthma / drug therapy*
-
Bronchodilator Agents / administration & dosage*
-
Bronchodilator Agents / adverse effects
-
Delayed-Action Preparations
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Metered Dose Inhalers
-
Middle Aged
-
Peak Expiratory Flow Rate / drug effects*
-
Quality of Life
-
Salmeterol Xinafoate
-
Terbutaline / administration & dosage
-
Terbutaline / adverse effects
-
Terbutaline / analogs & derivatives*
-
Treatment Outcome
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents
-
Bronchodilator Agents
-
Delayed-Action Preparations
-
tulobuterol
-
Salmeterol Xinafoate
-
Terbutaline
-
Albuterol